SCHEMBL1895334

SCHEMBL1895334

CCOC(=O)n1nc(NC(=O)c2ccc(N3CCN(C(=O)C(F)(F)F)CC3)cc2[N+](=O)[O-])c2c1CCN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.39
ALDH1A1 P00352 5/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.36
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
PDK2 Q15119 1/20 0.34
TSHR P16473 1/20 0.34
ATM Q13315 1/20 0.34
MGLL Q99685 1/20 0.34
MET P08581 1/20 0.34
BCL2 P10415 1/20 0.34
BCL2L1 Q07817 1/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
POLB P06746 1/20 0.34
GPR174 Q9BXC1 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1890065 0.92 SIRT6 (0.40) MAPTALDH1A1LMNASMN1; SMN2POLB
SCHEMBL1891508 0.90 MTOR (0.40) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL1888067 0.85 IGF1R (0.42) MAPTALDH1A1LMNASMN1; SMN2MEN1
Trifluoroacetic Acid SCHEMBL2679044 0.85 MAPT (0.35) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL1890828 0.84 AKR1B10 (0.40) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL1890661 0.84 MAPT (0.35) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL2454525 0.83 ALDH1A1 (0.44) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL1889538 0.82 KIT (0.39) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL1892408 0.81 F12 (0.32) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL1898452 0.81 TP53 (0.34) MAPTMGLLGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 US disclosed
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 US disclosed
EP-1968976-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-09-17 EP disclosed
WO-2007068619-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 MAPT 2600/4885ALDH1A1 2295/4885LMNA 3253/4885
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K19 MAPT 2600/4885ALDH1A1 2295/4885LMNA 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.